

# Appendix 3Y

## Change of Director's Interest Notice

*Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.*

Introduced 30/09/01 Amended 01/01/11

<b>Name of entity</b>	Imagion Biosystems Limited
<b>ABN</b>	42 616 305 027

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

<b>Name of Director</b>	Robert Romeo Proulx
<b>Date of last notice</b>	30 September 2025

### Part 1 - Change of director's relevant interests in securities

*In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust*

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

<b>Direct or indirect interest</b>	Direct
<b>Nature of indirect interest (including registered holder)</b> Note: Provide details of the circumstances giving rise to the relevant interest.	N/A
<b>Date of change</b>	29 December 2025

**Appendix 3Y**  
**Change of Director's Interest Notice**

<b>No. of securities held prior to change</b>	<ol style="list-style-type: none"> <li>1. 3,070,749 Ordinary Shares</li> <li>2. 50,000 Unlisted Performance Options, exercisable at \$1.12, vesting on 1 May 2022, expiring 1 May 2026.</li> <li>3. 50,000 Unlisted Performance Options, exercisable at \$1.12, vesting on 1 May 2022, expiring 1 May 2027.</li> <li>4. 50,000 Unlisted Performance Options, exercisable at \$1.12, vesting on 1 May 2023, expiring 1 May 2028.</li> <li>5. 2,000,000 Unlisted Performance Rights (expiring 22 August 2028), comprising of: <ol style="list-style-type: none"> <li>(a) 600,000 Class A (Share price of at least \$0.10 (10 cents) over 20 consecutive trading days);</li> <li>(b) 600,000 Class B (Market capitalisation of at least \$7.5 million over 20 consecutive trading days);</li> <li>(c) 800,000 Class C (Market capitalisation of at least \$12.5 million over 20 consecutive trading days).</li> </ol> </li> <li>6. 625,000 Options, exercisable at \$0.04 (4 cents), expiring 13 December 2027.</li> <li>7. 2,000,000 Unlisted Options, exercisable at \$0.012 (1.2 cents), expiring 29 May 2030, comprising of: <ol style="list-style-type: none"> <li>(a) 400,000 Options vesting on submission of MagSense@ HER2 IND for Phase 2 study (or equivalent regulatory submission for another jurisdiction);</li> <li>(b) 400,000 Options vesting on first patient dosed in a Phase 2 study;</li> <li>(c) 1,000,000 Options vesting on completion of a Phase 2 study; and</li> <li>(d) 200,000 Options vesting on submission of an IND (or like regulatory approval) for a second imaging agent.</li> </ol> </li> <li>8. 1,666,667 Listed Options, exercisable at \$0.04 (4 cents), expiring 13 December 2027.</li> </ol>
<b>Class</b>	Ordinary Shares and Unlisted Performance Rights
<b>Number acquired</b>	1,400,000 Ordinary Shares
<b>Number disposed</b>	600,000 Class B Unlisted Performance Rights; and 800,000 Class C Unlisted Performance Rights.

+ See chapter 19 for defined terms.

**Appendix 3Y**  
**Change of Director's Interest Notice**

<b>Value/Consideration</b> Note: If consideration is non-cash, provide details and estimated valuation	Nil
<b>No. of securities held after change</b>	<ol style="list-style-type: none"> <li>1. 4,470,749 Ordinary Shares</li> <li>2. 50,000 Unlisted Performance Options, exercisable at \$1.12, vesting on 1 May 2022, expiring 1 May 2026.</li> <li>3. 50,000 Unlisted Performance Options, exercisable at \$1.12, vesting on 1 May 2022, expiring 1 May 2027.</li> <li>4. 50,000 Unlisted Performance Options, exercisable at \$1.12, vesting on 1 May 2023, expiring 1 May 2028.</li> <li>5. 600,000 Unlisted Class A Performance Rights (expiring 22 August 2028), vesting if the company's share price is at least \$0.10 (10 cents) over 20 consecutive trading days.</li> <li>6. 625,000 Options, exercisable at \$0.04 (4 cents), expiring 13 December 2027.</li> <li>7. 2,000,000 Unlisted Options, exercisable at \$0.012 (1.2 cents), expiring 29 May 2030, comprising of: <ol style="list-style-type: none"> <li>(a) 400,000 Options vesting on submission of MagSense@ HER2 IND for Phase 2 study (or equivalent regulatory submission for another jurisdiction);</li> <li>(b) 400,000 Options vesting on first patient dosed in a Phase 2 study;</li> <li>(c) 1,000,000 Options vesting on completion of a Phase 2 study; and</li> <li>(d) 200,000 Options vesting on submission of an IND (or like regulatory approval) for a second imaging agent.</li> </ol> </li> <li>8. 1,666,667 Listed Options, exercisable at \$0.04 (4 cents), expiring 13 December 2027.</li> </ol>
<b>Nature of change</b> Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back	Issue of Ordinary Shares following the vesting of Class B and Class C Performance Rights.

+ See chapter 19 for defined terms.

## Appendix 3Y

### Change of Director's Interest Notice

---

#### Part 2 – Change of director's interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of “notifiable interest of a director” should be disclosed in this part.

<b>Detail of contract</b>	N/A
<b>Nature of interest</b>	N/A
<b>Name of registered holder (if issued securities)</b>	N/A
<b>Date of change</b>	N/A
<b>No. and class of securities to which interest related prior to change</b> <small>Note: Details are only required for a contract in relation to which the interest has changed</small>	N/A
<b>Interest acquired</b>	N/A
<b>Interest disposed</b>	N/A
<b>Value/Consideration</b> <small>Note: If consideration is non-cash, provide details and an estimated valuation</small>	N/A
<b>Interest after change</b>	N/A

#### Part 3 – <sup>+</sup>Closed period

<b>Were the interests in the securities or contracts detailed above traded during a <sup>+</sup>closed period where prior written clearance was required?</b>	N/A
<b>If so, was prior written clearance provided to allow the trade to proceed during this period?</b>	N/A
<b>If prior written clearance was provided, on what date was this provided?</b>	N/A

---

<sup>+</sup> See chapter 19 for defined terms.